CY-QUANT VASP/P2Y12

    default
    Référence
    7502
    Statut
    CE
    Sample
    160 µl de sang total citraté
    Quantité
    1 to 23 tests/run
    Detection
    ELISA
    Application
    Kit ELISA
    Composition

    Microplaque coatée, PGE1, PGE1 + ADP, Tampon de lyse, Solution de lavage, Tampon de dilution, Anti-VASP-P-peroxydase, Solution stop, outil pour extraction des puits de leur barrette support

    CY-QUANT VASP/P2Y12 est dédiée au dosage des antagonistes spécifiques du récepteur plaquettaire à l’ADP, P2Y12. La protéine intra-plaquettaire VASP (Vasodilator Stimulated Phosphoprotein) est non phosphorylée à l’état basal. La prostaglandine E1 (PGE1) induit la phosphorylation de VASP tandis que la fixation de l'adénosine diphosphate (ADP) sur les récepteurs P2Y12 entraîne la déphosphorylation de VASP. Dans les conditions du test et lors de l'ajout simultané de PGE1 et d'ADP, l'effet de l'ADP prévaut et induit la déphosphorylation de VASP, à moins que le récepteur P2Y12 soit efficacement bloqué par des drogues anti-plaquettaires ciblant ce récepteur (comme les thiénopyridines). Le niveau de phosphorylation de VASP dans cette condition reflète donc le niveau d'inhibition du récepteur P2Y12.

    Date Nom du document Téléchargement
    01/12/2017 Package insert CY-QUANT VASP P2Y12 DE (144.01 KB)
    EN (131.77 KB)
    ES (134.38 KB)
    FR (135.60 KB)
    IT (132.75 KB)
    PT (135.36 KB)
    01/09/2013 Flyer CY-QUANT VASP P2Y12 EN (726.86 KB)
    Auteur Titre Année d'édition Revue
    Barragan P. et al
    Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity
    2010
    Thromb. Haemost
    Jakubowski J.A. et al
    Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated
    2012
    Thromb. Haemost
    Abtan J et al
    Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein
    2013
    Thromb Haemost
    Hobl E.L et al
    Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake
    2013
    Cytometry
    Gaussem P et al.
    Inefficacy of Platelet Transfusion to Reverse Ticagrelor
    2015
    N Engl J Med
    Söderlund et al
    In vitro anti-platelet potency of ticagrelor in blood samples from infants and children
    2015
    Thromb Research
    Bonello L et al
    Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome
    2015
    Thromb Haemost
    Umemura K & Iwaki T.
    The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
    2016
    Clin Pharmacol Drug Dev
    Singh D. & Silakari O.
    Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity
    2017
    Bioorg. Med. Chem.
    Ding P. et al.
    Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population
    2017
    Clin Appl Thromb Hemost.
    Deharo P. et al
    Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study
    2017
    JACC Cardiovasc Interv.
    Takehiko Nagao et al
    A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial – PRASTRO-I trial
    2018
    Expert Opinion on Pharmacotherapy
    Deepak L. Bhatt et al
    Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
    2019
    The New England Journal of Medicine
    Holm M. et al
    The MOVEMENT Trial
    2019
    Journal of the American Heart Association
    Ito Y. et al
    Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats.
    2018
    International Journal of Scientific Reports
    Bonello L. et al
    Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients.
    2017
    Thrombosis Research
    Zeymer U. et al
    Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention
    2015
    JACC: Cardiovascular Interventions
    Martin A. et al.
    Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach
    2020
    Eur J Pharmacol.